Also, it has recently been shown that ARID1A mutations can render cancer cells sensitive to glutathione and glutamate-cysteine ligase synthetase catalytic subunit (GCLC) inhibitors [37], while they also increase the sensitivity of cancer cells to PI3K inhibitors [38]. This evidence concerns the gene ARID1A and cancer.